396 related articles for article (PubMed ID: 23807265)
21. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Le Calvé B; Rynkowski M; Le Mercier M; Bruyère C; Lonez C; Gras T; Haibe-Kains B; Bontempi G; Decaestecker C; Ruysschaert JM; Kiss R; Lefranc F
Neoplasia; 2010 Sep; 12(9):727-39. PubMed ID: 20824049
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF
J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363
[TBL] [Abstract][Full Text] [Related]
23. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
24. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
[TBL] [Abstract][Full Text] [Related]
26. Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.
Kerschbaumer J; Freyschlag CF; Bauer R; Obwegeser AA; Schubert GA; Thomé C; Seiz M
Anticancer Res; 2012 Dec; 32(12):5515-9. PubMed ID: 23225460
[TBL] [Abstract][Full Text] [Related]
27. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
Costa BM; Caeiro C; Guimarães I; Martinho O; Jaraquemada T; Augusto I; Castro L; Osório L; Linhares P; Honavar M; Resende M; Braga F; Silva A; Pardal F; Amorim J; Nabiço R; Almeida R; Alegria C; Pires M; Pinheiro C; Carvalho E; Lopes JM; Costa P; Damasceno M; Reis RM
Oncol Rep; 2010 Jun; 23(6):1655-62. PubMed ID: 20428822
[TBL] [Abstract][Full Text] [Related]
30. Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
Sakamoto N; Ishikawa E; Yamamoto T; Satomi K; Nakai K; Sato M; Enomoto T; Morishita Y; Takano S; Ohno T; Tsuboi K; Matsumura A
Neurol Med Chir (Tokyo); 2011; 51(4):319-25. PubMed ID: 21515959
[TBL] [Abstract][Full Text] [Related]
31. The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma.
Wu Q; Berglund AE; Etame AB
Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361090
[TBL] [Abstract][Full Text] [Related]
32. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Dehdashti AR; Hegi ME; Regli L; Pica A; Stupp R
Neurosurg Focus; 2006 Apr; 20(4):E6. PubMed ID: 16709037
[TBL] [Abstract][Full Text] [Related]
33. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Gao Y; Fotovati A; Lee C; Wang M; Cote G; Guns E; Toyota B; Faury D; Jabado N; Dunn SE
Mol Cancer Ther; 2009 Dec; 8(12):3276-84. PubMed ID: 19996271
[TBL] [Abstract][Full Text] [Related]
36. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
[TBL] [Abstract][Full Text] [Related]
37. Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Cheng Q; Ma X; Cao H; Chen Z; Wan X; Chen R; Peng R; Huang J; Jiang B
Mol Med Rep; 2017 Feb; 15(2):597-604. PubMed ID: 28035389
[TBL] [Abstract][Full Text] [Related]
38. Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006.
Yabroff KR; Harlan L; Zeruto C; Abrams J; Mann B
Neuro Oncol; 2012 Mar; 14(3):351-9. PubMed ID: 22241797
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
Wang Y; Chen X; Zhang Z; Li S; Chen B; Wu C; Wang L; Zhang X; Wang J; Chen L; Jiang T
Neurosurg Rev; 2014 Jan; 37(1):73-8. PubMed ID: 23912878
[TBL] [Abstract][Full Text] [Related]
40. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma.
Petrecca K; Guiot MC; Panet-Raymond V; Souhami L
J Neurooncol; 2013 Jan; 111(1):19-23. PubMed ID: 23054563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]